HOUSTON, Aug. 12, 2026 /PRNewswire/ — Iterion Therapeutics, a clinical-stage oncology company dedicated to advancing first-in-class therapies targeting aberrant Wnt/β-catenin signaling, today announced the addition of two new Independent Board Members, Manuel Aivado, MD, PhD and Bob Smith.
HOUSTON, May 4, 2026 /PRNewswire/ — Iterion Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies for Wnt/β-catenin-driven cancers, today announced that tegavivint, a first-in-class small-molecule inhibitor of TBL1, will be featured in three presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29–June 2 in Chicago.
HOUSTON, April 13, 2026 /PRNewswire/ — Iterion Therapeutics announced that two abstracts featuring its first-in-class TBL1 inhibitor, tegavivint, will be presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. Each will highlight the company’s approach to targeting the Wnt/β-catenin pathway, one of the most frequently dysregulated signaling programs in cancer.
Tegavivint Targets the Central Oncogenic Driver in Colorectal Cancer as First-in-Class Clinical-Stage Wnt/β-Catenin Inhibitor CRC Expansion Builds on Promising Monotherapy Activity and Favorable Safety Profile Observed in Advanced Hepatocellular Carcinoma HOUSTON, March 25, 2026 /PRNewswire/ — Iterion Therapeutics, a clinical-stage, biopharmaceutical company dedicated to advancing the treatment of Wnt-driven cancers, today reported that the first patient has been …
Tegavivint Is the First Wnt/β-Catenin Inhibitor to Demonstrate Tolerability and Monotherapy Clinical Activity in Complex Solid Tumors Osteosarcoma Program Builds on Clinical Benefit observed in Lead Indication of Advanced Hepatocellular Carcinoma HOUSTON, Feb. 10, 2026 /PRNewswire/ — Iterion Therapeutics, a clinical-stage, biopharmaceutical company dedicated to revolutionizing the treatment of Wnt-driven cancers, today announced that the first patient has …
Iterion is excited to present new data on Tegavivint at the upcoming AACR–NCI–EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 22–25 in Boston. Our Chief Scientific Officer, Stephen Horrigan, and Senior Director of Translational Research and Non-Clinical Development, Aundrietta Duncan, will share findings highlighting Tegavivint’s first-in-class mechanism and activity in advanced hepatocellular carcinoma (aHCC). Tegavivint, …
HOUSTON, Feb. 20, 2024 /PRNewswire/ — Iterion Therapeutics, an oncology-focused biopharmaceutical company developing small molecule inhibitors of Transducin beta-like protein 1 (TBL1), a downstream target in the Wnt/beta-catenin signaling pathway, announced today it is actively enrolling a Phase 1b/2a clinical trial of its lead molecule, tegavivint, in patients with advanced hepatocellular carcinoma (HCC) that have failed at least …
Iterion announces collaboration with Ohio State University Comprehensive Cancer Center-James Cancer Hospital & Solove Research Institute.
Iterion shares results from collaboration with Cancer Research UK (CRUK)
Results announced from dose escalation study of tegavivint in desmoid tumors.
